Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
Primary Care Physicians Face Tight Competition
Long hours and low pay make family practice an unappealing option for many aspiring physicians. According to a report from the Health Care Cost...
Next Generation Sequencing Tests to Receive Less Scrutiny
The U.S. Food and Drug Administration (FDA) will change its regulatory approach to next generation sequencing (NGS) tests, re-classifying them as moderate-risk medical devices....
FDA Expands Approval of Brentuximab Vedotin
The U.S. Food and Drug Administration (FDA) approved brentuximab vedotin as frontline therapy for adults with classic Hodgkin lymphoma (HL) in combination with chemotherapy....
Canadian Pharmacy Fined for Illegal Imports
Canada Drugs – an online pharmacy based in Winnipeg that sells and ships medications internationally –was fined $5 million, sentenced to five years of...
Walmart-Humana Deal Could Threaten Hospital Services
A deal between Walmart and Humana, a large insurance company that offers private Medicare plans, may soon be on the table. Walmart could pay...
Current Issue
April 2018, Volume 4, Issue 5
This issue features a look at the U.S. health-care system’s transition from a paper-based system to electronic health records, an introduction to a series about oncology nurse practitioners, and more.
